In B-cell lymphoma, 3-Deazaneplanocin A (DZNep) and ibrutinib could inhibit EZH-mediated methylation of lncRNA FAS-AS1 promoter and upregulate FAS-AS1, thus enhancing FAS-mediated apoptosis of cancer cells 82, 115, 116. This evidence concerns the gene FAS and B-cell non-Hodgkin lymphoma.